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Abstract
Background: Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene
encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with the most
prominent being Miyoshi myopathy (MM) and limb girdle muscular dystrophy type 2B (LGMD2B).
Methods: We assessed the one-year-natural course of dysferlinopathy, and the safety and efficacy of deflazacort
treatment in a double-blind, placebo-controlled cross-over trial. After one year of natural course without
intervention, 25 patients with genetically defined dysferlinopathy were randomized to receive deflazacort and
placebo for six months each (1 mg/kg/day in month one, 1 mg/kg every 2nd day during months two to six) in one
of two treatment sequences.
Results: During one year of natural course, muscle strength declined about 2% as measured by CIDD (Clinical
Investigation of Duchenne Dystrophy) score, and 76 Newton as measured by hand-held dynamometry. Deflazacort
did not improve muscle strength. In contrast, there is a trend of worsening muscle strength under deflazacort
treatment, which recovers after discontinuation of the study drug. During deflazacort treatment, patients showed a
broad spectrum of steroid side effects.
Conclusion: Deflazacort is not an effective therapy for dysferlinopathies, and off-label use is not warranted. This is
an important finding, since steroid treatment should not be administered in patients with dysferlinopathy, who
may be often misdiagnosed as polymyositis.
Trial registration: This clinical trial was registered at www.ClincalTrials.gov, identifier: NCT00527228, and was always
freely accessible to the public.
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Introduction
Dysferlinopathies are autosomal recessive muscular
dystrophies caused by mutations in the gene encoding
dysferlin (DYSF; Online Mendelian Inheritance in Man
[OMIM] gene number 603009, Chr 2p13, GenBank
NM_003494.2) [1,2]. Dysferlinopathies are rare muscular
dystrophies, as the number of adult patients is estimated
between 1/100,000 to 1/200,000 [3]. Miyoshi myopathy
[4] (MM) and distal anterior compartment myopathy [5]
(DMAT), both allelic distal muscle disorders that
preferentially affect the gastrocnemius or tibial muscle,
and limb girdle muscular dystrophy (LGMD) type 2B with
characteristic proximal weakness at onset [1,2] represent
different phenotypic presentations of dysferlinopathy.
Dysferlinopathy arises from mutations in the dysferlin
gene, which contains 55 exons and spans a region of
150 kb. The clinical picture is usually less severe than
most other autosomal recessive LGMD forms, although
there is a wide intra- and interfamilial variability [6]. Con-
finement to wheelchair may occur, on average 10–20 years
after onset of the disease. Cardiac and respiratory muscles
are not involved in the majority of patients, and patients
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have normal intelligence. Serum creatine kinase (CK) is
always considerably elevated even in the pre-clinical
stages. Muscle biopsies typically show dystrophic patterns,
additionally, inflammatory changes are frequently seen [7].
Protein analyses in LGMD2B usually show a total defi-
ciency of dysferlin, both through immunohistochemistry
and immunoblotting, but partial deficiency is observed in
some patients. A large mutational spectrum with more than
400 different sequence variants in the DYSF gene has been
reported [8]. However, identical mutations in patients even
within the same family expressing LGMD2B or MM
phenotypes may suggest a role for modifier genes [9].
So far, the natural course of the disease and the mean
decline in muscle strength and daily-life activities have
only been described in a larger cohort of clinically, but
not genetically identified dysferlinopathy patients [10].
Steroids have proven efficacy in Duchenne muscular
dystrophy (DMD) [11,12,13], possibly due, at least in
part, to the anti-inflammatory effect of the drug. How-
ever, immunosuppressive agents such as azathioprine
and cyclosporine did not result in a similar increase of
muscle strength as observed with steroids [14,15]. It was
hypothesized that steroids may have other or additional
modes of action in DMD such as a membrane-
stabilizing effect [16]. Dysferlinopathies show marked
inflammation in muscle biopsy [7]. Anecdotal reports
have suggested that steroids do not improve muscle
strength in dysferlinopathy patients, but this was not
fully explored in a randomized, controlled trial [17].
This clinical trial was conducted for assessment of
the natural course of the disease during a one-year
pre-treatment phase and for evaluation of efficacy and
side effects of deflazacort in patients with dysferlinopathy.
We wanted to assess if deflazacort treatment results
in improvement of muscle strength and function
compared to placebo.
Methods
Study population and inclusion criteria
25 patients (12 male, 13 female) from 18 different
families between 20 and 60 years (mean age 32.4 ± 9.2)
with clinical, immunohistochemical, immunoblot and
genetic criteria of dysferlinopathy were included in the
clinical trial. Three patients presented with MM, two
with DMAT phenotype, while the remaining 20 patients
mainly showed LGMD involvement. Eight patients had
homozygous, 15 patients compound heterozygous muta-
tions in the dysferlin gene; in two patients (patient 1 and 2,
siblings), only one heterozygous mutation was detected,
since the second described genetic modification may only
represent a polymorphism. Within the patients with com-
pound heterozygous mutations, deletion of exon 31
was detected in one patient. In two patients, three
compound heterozygous pathogenic dysferlin muta-
tions were detected (see patient details in Figure 1).
HyperCKemia was noted in nine of our patients between
4 and 19 years prior to disease onset. Patients <18 years of
age, confined to bed or wheelchair, with other neurologic
or internal diseases or with former or current steroid
treatment were not included. Criteria for premature
discontinuation of the trial were withdrawal of informed
consent or lack of compliance.
The clinical trial was approved by regulatory authorities
and ethics committees at the Ludwig-Maximilians
University of Munich and conducted in accordance
with the Good Clinical Practice Guidelines. This clinical
trial was registered at www.ClincalTrials.gov, identifier:
NCT00527228 and was always freely accessible to the
public. The objectives, study design, risks and benefits
of participation were explained to all patients and
parents, and their written informed consent was
obtained before enrolment.
Study-design
The clinical trial is designed as a prospective, double-blind,
randomized, placebo-controlled cross-over trial. The cross-
over design was chosen for several reasons: a) patients with
dysferlinopathy are extremely rare, therefore, a sufficient
power can be reached with a small sample size by the
chosen design, b) in a cross-over design, each patient can
serve as his/her own control, c) the willingness to take part
in a clinical study is much higher in a cross-over design,
since each patient will receive the study drug. In a 12-
months pre-treatment phase, the natural history of the
disease was assessed. The 12-month visit served as a base-
line control prior to treatment; during the two cross-over
treatment periods response to treatment was evaluated by
comparing evaluations at start and end of each period. All
examinations took place at the principal investigator’s cen-
ter, the other six participating centers helped with patient
recruitment and transfer to the clinical trial center.
All patients had a one-year follow-up of natural history
with examinations in six-months intervals prior to the
treatment phase. After one year, patients were randomized
to six months deflazacort or placebo; after a three-months
wash-out, there was cross-over to the alternate treatment
(Figure 2).
Study drug
Since weight gain could be less pronounced in deflazacort
treatment compared to other steroids [13], we decided for
deflazacort as study drug, and for an alternate day regimen
(month 2 to month 6: 1 mg/kg every 2nd day) after the
loading phase (month 1: 1 mg/kg/day), since significant
improvement of strength along with only mild side effects
have been reported with this treatment schedule [11,18].
In contrast to the results of alternate-day therapy with
prednisone (1.25 and 2.5 mg/kg every other day) [19],
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Angelini et al. [18] used a dosage of deflazacort of
2.0 mg/kg every other day and showed sustained improve-
ment over 2 years, including improvement in average
muscle strength and in timed function testing [20].
Methods
Testing was performed by two experienced neurologists
after sufficient training with clinical trial procedures.
The investigators in the clinical trial center were trained
by the MD-NET Clinical Trials Coordination Centre
(CTCC) (www.md-net.org), inter-rater and intra-rater
variability was assessed prior to the clinical trial, and
reassessed 12-monthly during the trial period on the
enrolled dysferlinopathy patients; the results did now
show a relevant variability between tests.
During the pre-treatment phase in 6-month-intervals
the natural history of the disease was assessed, and
before and after each treatment period the response to
treatment was evaluated, using primary and secondary
outcome measures.
Primary outcome measures were manual muscle strength
assessed bilaterally by the modified Medical Research
Council Scales (MRC) CIDD (Clinical Investigation of
Duchenne Dystrophy) score [21], graded from 0 (worst) to
10 (best) (http://www.researchrom.com/masterlist/view/4),
and quantitative strength assessed by hand-held
dynamometry [22] (HHD) (Citec, Groningen, NL) in the
same muscle groups (deltoid, biceps brachii, brachioradialis,
triceps brachii, hand extensors and flexors, finger extensors
and flexors, neck extensors and flexors, quadriceps femoris,
iliopsoas, glutaeus maximus, hamstring muscles, tibial
anterior muscles, gastrocnemius). HHD was measured
in N (Newton), results were indicated as maximum N.
Measurements were repeated three times, and the best
result was valued.
Secondary outcome measures were quantitative muscle
strength measurement assessed by torque measurement [23]
(QSMT), (M3diagnos, Schnell Company, Germany) (http://
www.researchrom.com/masterlist/view/17), Neuromuscular
Symptoms Score [24] (NSS) (http://www.researchrom.com/
masterlist/view/9), Timed Function Tests [25], Vignos Scale
[26], Hammersmith Motor Ability Score [27], Clinical
Global Impressions (CGI) [28] and Quality of Life by
SF-36 German version [29] (http://www.researchrom.
com/masterlist/view/54).
Quantitative Strength Measurement Testing (QSMT)
was assessed using the Multi Muscle Tester M3 Diagnos
System. Maximum bilateral strength of biceps and
quadriceps muscle was measured isometrically by torque
measurement; results were indicated as% of maximum
torque difference. Measurements were repeated three
times, the best result was valued.
Handgrip strength was measured using the Jamar
Hydraulik Handgrip (Sammons Priston Company,
Figure 1 Description of the study population.
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Bolingbrook, Ireland). Grip strength can be assessed
from 0 to 90 kg, and the maximum value is
recorded automatically.
Daily-life activities were evaluated by the Neuromuscular
Symptom and Disability Functional Score (NSS). The NSS
lists 14 daily-life activities and grades them from no
disability to severe disability in 4 categories (total
score: 0 = severe disability, 42 = no disability).
Timed tests comprised of getting up from lying and
sitting position, running 10 meters and climbing four
stairs and were measured by stop watch.
The Vignos scale grades the patient’s walking ability
from 1 to 9 (1 = independent walking and climbing
stairs, 9 = wheelchair-bound).
Hammersmith motor ability score (HMAS)
The scale consists of 20 items (patient lifts head, rolls
prone to supine / supine to prone, gets to sitting from
lying, sits, gets up from floor, stands, stands on heels/
toes/one leg, hops on one leg, gets up from a chair,
walks upstairs/downstairs) each scored on a 3 point
scoring system. Each activity scores 2 for unaided, 1 for
assistance and 0 for inability. The only exceptions are
the activities of lying from sitting and lifting the head
from prone, in which 1 cannot be scored. A total score can
be achieved by summing the scores for all the individual
items. The total score can range from 0, if all activities fail,
to 40, if all the activities are achieved.
The Clinical Global Impression (CGI) is rated by the
investigator on a 4-7-point scale, with the severity of illness
scale using a range of responses from 1 (normal) through
to 7 (amongst the most severely ill patients). CGI change
scores range from 1 (very much improved) through to 7
(very much worse).
The health-related SF-36 is a multi-purpose, short-form
health survey with 36 questions. It yields an 8-scale profile
of functional health and well-being scores as well as
psychometrically-based physical and mental health
summary measures. It is a generic measure, as opposed to
one that targets a specific age, disease, or treatment group.
Accordingly, the SF-36 has proven useful in surveys of
general and specific populations, comparing the relative
burden of diseases, and in differentiating the health
benefits produced by a wide range of different treatments
(http://www.sf-36.org).
Laboratory testing
On each study visit, safety laboratory testing for selected
electrolytes, liver, kidney and inflammation analytics and
hematology variables (sodium, potassium, creatinine,
urea, ASAT, ALAT, GGT, CK, ESR, CRP, blood cell
count) were performed, and adverse events were
recorded. Genetic testing for dysferlin was carried out
for all patients by the Department of Human Genetics at
the University of Würzburg. All 55 coding exons and
flanking splice regions of the dysferlin gene were amplified
with exon-specific primers, followed by direct sequencing
on both strands. If only one mutation was found by
sequencing, gene dosis was measured for most of the
exons using the MLPA kit P268-A1 from MRC Holland.
Statistics
Randomization to the two sequences of treatment was
done by the MD-NET Clinical Trials Coordination
Centre (CTCC) (www.md-net.org) using the SAS 8
statistical package procedure “PROG PLAN”. After
screening for eligibility, patients were randomly
assigned at a 1:1 ratio to receive either deflazacort or
placebo for the first treatment phase. Patients baseline
Figure 2 Flow chart of the clinical trial.
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characteristics with regard to sex, age, body weight and
muscle strength assessed by CIDD and HHD did not
show relevant differences between treatment groups.
The study drug and the placebo preparation were
disposed by the hospital pharmacy, a number was
communicated to identify the study drug for each
patient, and the drug was identically prepacked to main-
tain the masking for the patient and investigator. To
maintain the masking for the trial statistician, reading
permission was withdrawn from the computer directory
containing randomization information.
The data of all visits were summarized descriptively,
using arithmetic mean and standard deviation for
numeric data (including changes within each trial period
(natural history, crossover periods 1 and 2)) and absolute
and relative frequencies for categorical data. For
crossover analyses, a mixed model [30,31] was applied
with the sequence of the two treatments within the
crossover design, the two treatment periods and
treatment (deflazacort or placebo) as fixed factors and
patients nested within sequence as random factor. This
procedure was also chosen to substitute missing values
in four patients of this study. The intention-to-treat
(ITT) population was used for the efficacy analyses of
the two primary endpoints. In addition, a non-
parametric procedure25 was applied which allows to
assess the treatment effect, the carry-over effect from
period 1 to period 2 (utilizing Wilcoxon U-tests) and the
period effect (via signed rank tests) within the crossover
design. The selection of this analysis procedure was
mainly based upon the small sample size of this trial
with non-normal distribution of the outcome measures.
The per-protocol population (PP) was used for all
efficacy analyses of secondary endpoints as specified in
the study protocol. This includes all patients who have
completed the second crossover period.
Sample size considerations
The clinical trial intended to show superior efficacy of
deflazacort over placebo in the 2 primary endpoints. The
available literature on clinical trials in the investigated
indication did not provide sufficiently valid data
whereon a statistical sample size calculation could be
based. Therefore, sample size calculation was based on
effect size consideration. An effect size of d = δ/σ = 0.5
represents a moderate superiority of deflazacort
compared to placebo according to Cohen [32]. Effect
sizes below d = 0.5 are usually considered as clinically
not meaningful, effect sizes of d > 0.8, on the other side,
would be associated with clinically relevant benefit of
the deflazacort treatment. To demonstrate a difference
between deflazacort and placebo with an effect size of at
least 0.5 in a crossover design, a number of N = 30
patients were planned to complete the trial with the
2nd crossover period. The following assumptions are
made for this sample size determination: α = .0125
(1-sided, adjusted according to Bonferroni-Holm for
2 primary outcome measures), 1-ß = 80%, d = δ/σ ≈ 0.5
and a correlation between the outcome measures in the 2
crossover periods of ρ ≈ 0.6). Allowing a drop-out rate of
about 20%, we have aimed for a total sample size of 35
patients. Previous studies in DMD patients using higher
daily dose steroid regimen reported drop-out rates of less
than 6% [12].
Results
The recruitment of 35 patients was more difficult than
expected; only 25 patients were included between
September 2003 and February 2008. However, no patient
showed improvement of muscle strength – although
blinding was sustained, it became clear, that the study
drug did not have a positive effect, and may even have a
negative effect on muscle strength. Therefore, a condi-
tional power calculation based on the first 18 patients
was performed in February 2008 for answering the
following question: is it feasible according to the interim
results, that an efficacy of deflazacort versus placebo can
be proven, if the clinical trial will be conducted as
scheduled (recruitment of 10 more patients)? The result
of the power analysis showed that the probability for
proving efficacy of deflazacort versus placebo was highly
unlikely, even if the clinical trial was continued
according to plan. Therefore, we decided to terminate
the study and perform a final analysis with all available
data (stop for futility). Before the final decision was
reached to close the clinical trial, another seven patients
were included to the natural course part or proceeded to
the medication phase. However, the data of these
patients was not included in the interim analysis, since
only participants who completed the full trial period
were analyzed. In total, 37 patients were screened for
this study. Twelve patients could not be included due to
loss of ambulation (n = 5), earlier use of steroids (n = 3),
lack of compliance (n = 4). Of 25 patients who entered
the natural history phase, none discontinued this part of
the trial prematurely; two patients had only just finished
the natural history phase, when the trial was discontinued;
23 patients were randomized into the crossover treatment.
The final analysis population consists of 23 patients, of
whom four (patients 12, 13, 21, 23) had not fully completed
both treatment phases at the date of the interim analysis,
two under deflazacort, and two under placebo.
Primary efficacy variables
Muscle strength assessed by CIDD
Initial testing of manual muscle strength assessed by CIDD
in both groups (sequence deflazacort-placebo, and placebo-
deflazacort) showed not much difference between the two
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groups regarding basic muscle strength (between 77%
and 80% CIDD). All patients declined during the natural
history, at 6 months and even more pronounced at
12 months. In the deflazacort-placebo sequence, patient’s
strength declined during deflazacort treatment, partly
recovered during the steroid wash-out, but further declined
during placebo administration. Patients in the placebo-
deflazacort sequence constantly lost strength over the
entire trial duration. None of these differences were
significant; there was a numerical trend to a slightly larger
loss (by 1.2 units in the CIDD) during deflazacort
treatment compared to placebo (Figure 3a; change be-
tween start and end of pooled crossover periods:
deflazacort: d = −2.24; standard deviation (SD) = 3.0;
placebo: d = −1.00, SD = 2.2; mixed model result (ITT):
p(treatment) = 0.1558; 95% confidence interval [−3.01;
0.52] in disfavor of deflazacort; non-parametric analysis
(PP): p = 0.4375). During the one-year natural history,
CIDD declined approximately by −2%, during the whole
trial duration of 27 months (natural history, both sequences
and three-months wash-out), CIDD declined approximately
by −5% (Figure 3b).
Assessing percentage of patients with increase or
decline of strength as measured by CIDD during natural
history and both sequences, we found that during the
one-year natural history, 78% of patients declined in
strength as measured by CIDD, during six months
placebo, 67% of patients deteriorated, but during six
months deflazacort, slightly more patients (81%) got worse
than during one year of natural course (data not shown).
Hand-held dynamometry (HHD)
HHD showed that muscle strength in all patients
decreased during the natural history, more obvious after
12 than six months. In both treatment sequences,
patients strength decreased, partly recovered during the
steroid wash-out in sequence deflazacort-placebo, and
further decreased during placebo, but more prominent
during deflazacort administration (Figure 4a: change
between start and end of pooled crossover periods:
deflazacort: d = −67.7; SD = 67.6; placebo: d = −26.7,
SD = 73.9; mixed model result (ITT): p(treatment) = 0.0546;
95% confidence interval [−76.50; 0.84] in disfavor of
deflazacort; non-parametric analysis (PP): p = 0.1309).
The pooled sequences for absolute change in HHD
showed a decline of 72 N during the one-year observation
period and by 167 N during the whole trial duration of
27 months (Figure 4b).
In summary, for none of the primary efficacy variables a
statistically significant difference could be demonstrated in
this trial. The mean changes and the related 95% confi-
dence intervals indicate a quantitatively larger improvement
under placebo compared to Deflazacort.
Secondary outcome variables
The comparison between deflazacort and placebo in all
secondary outcome measures are summarized in Table 1.
Changes in each crossover-period were similar under
Deflazacort and Placebo. The only two variables showing
a slight (p < 0.10) difference between the two treatments
are the Vignos Scale and the Hammersmith Motor Ability
Score in favor of placebo. In general, the worsening of the
scores in all secondary outcome measures which was
observed during the 1-year natural course evaluation
continued during the 15 months crossover phase under
either treatment.
Muscle strength measurement assessed by torque
measurement (QSMT) and Handgrip force measurement
Handgrip of right and left hand mainly mirrored the results
of CIDD and HHD. However, QSMT in biceps and quadri-
ceps muscles bilaterally showed inconsistent changes.
Neuromuscular symptom score (NSS)
The NSS lists 14 daily-life activities and grades them
from no disability to severe disability in 4 categories. In
both groups, NSS decreased more during deflazacort
than during placebo administration, with a trend to
recovery during the wash-out in the deflazacort-placebo
sequence (Figure 5a).
Timed function tests
Timed tests (getting up from lying and sitting position,
running 10 m and climbing 4 stairs) showed mild
worsening during the complete trial course, but no
differences in decline between natural course and
treatment phases.
Vignos scale and Hammersmith motor ability score
Vignos scale and Hammersmith Motor Ability Score
worsened more during deflazacort treatment than under
placebo (p = 0.0578 in the non-parametric test for
treatment differences). The Hammersmith Motor
Ability Score showed overall worsening, not restricted
to walking ability.
Clinical global impressions (CGI) of change
The global ratings of the disease severity by the investi-
gator did not show relevant differences between the
two treatments.
Quality of life by SF-36 German version
The subscales and the standardized component
scales show the following results taking the range of
the scales between 0 (very low quality of life) and 100
(very good quality of life) into account (Table 2):
At baseline, dysferlinopathy patients reported impairment
of physical functioning and in general health perceptions.
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Deflazacort
Deflazacort
Deflazacort
Deflazacort
Placebo
Placebo
Figure 3 (See legend on next page.)
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Compared with a normative sample for the German
population25, the physical standardized component
scale values were more than one standard deviation
below the general population values and are comparable
to mean values of patients suffering from other chronic
diseases like cardiac diseases (myocardial infarction,
angina pectoris), or diabetes. No impairment was seen
with regard to the mental standardized component scale
and the related SF-36 subscales.
During the 1-year natural history phase, the SF-36
ratings remained largely unchanged or they even
improved slightly (physical and emotional role function,
bodily pain, and general health perception). Under active
treatment with deflazacort, SF-36 ratings in all sub- and
component scales worsened as opposed to placebo treat-
ment where the ratings remained stable with a tendency
towards a slight improvement in most of the subscales
and standardized component scales
Statistical comparison of deflazacort and placebo
showed different changes in the subscales mental health
(psychological wellbeing) and the role emotional scale
(p < 0.05) in favour of placebo. In addition, we observed
tendencies towards slightly better quality of life rating
under placebo in the vitality subscale and the mental
standardized component scale.
Mutation-related subgroup analysis
We correlated the type of mutation, resulting in residual
dysferlin protein versus total loss of dysferlin protein,
assessed by Western Blot and mutation prediction
(Figure 1), with outcomes during both treatment phases.
We found in both sequences, more pronounced in the
placebo-deflazacort sequence, that patients with residual
dysferlin protein experienced more worsening than patients
with total absence of dysferlin protein (Figure 1, Figure 3c).
However, this was not a statistically significant finding, but
a trend, which was also seen in the other tests performed.
Worsening of participants with residual dysferlin
protein expression under steroid treatment was more
evident using the HHD assessment than in the CIDD
results (Figure 4c).
NSS worsening is more pronounced in both sequences
if residual dysferlin protein is present (Figure 5b). By
QSMT, there was no correlation between reduction in
strength and residual dysferlin protein (data not shown).
However, the sample size of these subgroups is very
small (4 to 6 patients) and therefore these analyses are
mainly helpful to generate hypotheses but not a description
of possible differences between mutation subgroups.
Laboratory findings
CK levels were markedly elevated in all patients, and con-
siderably decreased after deflazacort treatment, but did not
correspond with functional ratings (median decrease under
deflazacort = −801 units, under placebo = +70 (p = 0.0145).
No relevant changes were observed in safety laboratory
analytics during the treatment phases.
Adverse events
We assessed adverse events in all patients who were
treated with study medication (Table 3). We found mild
gastrointestinal side effects in four patients (n = 3 on
deflazacort, n = 1 on placebo), and weight gain in four
patients (n = 3 on deflazacort, n = 1 on placebo). In four
patients we saw acne, and two patients suffered from
increased blood pressure during deflazacort treatment.
In single patients, back pain, Cushingoid features,
tremor, fatigue, tachycardia, hair loss, headache and
sleep disturbances occurred, all during deflazacort
treatment. In six patients, muscle weakness was rapidly
progressing during deflazacort treatment, which was
not seen in any patient during placebo administration,
e.g. patient 4 was no more able to lift his head, while
patient 6 could no longer get up from sitting pos-
ition. Rapid deterioration of muscle strength was
noted as an adverse event in all six patients.
Discussion
In conclusion, during one year of natural course, muscle
strength declined about 2% as measured by CIDD, and
76 N as measured by HHD. These findings were
supported by comparable worsening of the secondary
outcome measurements Handgrip, NSS, Vignos Scale
and HMAS. Arguably, scores derived from manual
muscle testing do not represent interval data; thus one
cannot accurately measure percentage change. How-
ever, using more quantitative measures of strength
(See figure on previous page.)
Figure 3 Manual muscle strength assessed by CIDD in both groups in 18 patients (sequence deflazacort-placebo, and placebo-
deflazacort, completer population). a) Average course%CIDD sum score from natural history until end of both sequences. b) Pooled sequences
for absolute change%CIDD from natural history until end of both sequences. c) Mutation-related CIDD subgroup analysis. Correlation between
the type of mutation, resulting in residual dysferlin protein versus total loss of dysferlin protein, assessed by Western Blot and mutation
prediction, and outcomes during treatment phases with a sample size of 4 patients in 3 subgroups (sequence deflazacort-placebo, protein
present / sequence deflazacort-placebo, protein absent / sequence placebo-deflazacort, protein present) and 6 patients in the remaining
subgroup (sequence placebo-deflazacort, protein absent).
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demonstrated a similar lack of benefit as did the
other secondary outcome measures. Additionally,
Vignos and HMAS are fairly rough scales, not suitable
for identifying more subtle changes over a one year period
in a slowly progressive muscle disease. Vignos Scale and
HMAS both showed worsening, slightly in favor of
placebo. The Hammersmith Motor Ability Score thereby
showed overall worsening, not restricted to walking ability.
Interestingly, timed tests did not detect relevant changes il-
lustrating that tests measuring changes in complex activ-
ities in milliseconds may not perfectly mirror and have an
impact on changes in daily life. Additionally, QSMT by
torque measurement die not prove useful to detect reliable
changes. Patient-reported quality of life assessments
remained fairly unchanged during this first year or
improved slightly, mainly in the dimensions, which were
impaired in this study population (physical functioning,
mental health, standardized physical component scale).
Interestingly, CK levels remained stable during placebo
administration, and decreased during deflazacort treatment,
but non-corresponding with clinical improvement. This
finding confirms that steroids are not just ineffective in
dysferlinopathy, but show different activities, thereby
enhancing the internal validity of this clinical trial.
Non-recoverable loss of strength in patients with
dysferlin-deficiency, who were initially misdiagnosed as
inflammatory myopathy and treated with corticosteroids,
had been suggested by Hoffmann et al. [17] in an
uncontrolled series of 20 patients prior to this study.
Interestingly, we detected reduced dysferlin levels in
patients with inflammatory myopathies (polymyositis,
inclusion body myositis) treated with steroids (unpublished
(See figure on previous page.)
Figure 4 Hand-held dynamometry (HHD) in both groups in 18 patients (sequence deflazacort-placebo, and placebo-deflazacort,
completer population). a) Average course%HHD sum score from natural history until end of both sequences. b) Pooled sequences for absolute
change%HHD from natural history until end of both sequences. c) Mutation-related HHD subgroup analysis. Correlation between the type of
mutation, resulting in residual dysferlin protein versus total loss of dysferlin protein, assessed by Western Blot and mutation prediction, and
outcomes during treatment phases with a sample size of 4 patients in 3 subgroups (sequence deflazacort-placebo, protein present / sequence
deflazacort-placebo, protein absent / sequence placebo-deflazacort, protein present) and 6 patients in the remaining subgroup (sequence
placebo-deflazacort, protein absent).
Table 1 Comparison of deflazacort and placebo in secondary outcome measures (itt population)
Outcome measures Baseline† Natural course Deflazacort (pooled) Placebo (pooled) p-value
(N = 23) End of year
1 – begin*
End – begin
of crossover*
End – begin
of crossover*
Deflazacort
vs. placebo‡
(N = 23) (N = 21) (N = 21) (N = 19)
Muscle strength (CIDD) 78.5 ± 9.6 (56–89) −2.0 ± 2.5 −2.2 ± 3.0 - 1.0 ± 2.2 0.4375
Hand-held dynamometry (HDD) (N) 596 ± 267 (117–1206) −72.2 ± 109.6 −67.7 ± 67.6 - 26.7 ± 73.9 0.1309
QSMT – Torque Measurement
Handgrip left (kg) 20.1 ± 10.3 (8–52) −2.2 ± 3.6 −1.9 ± 2.9 −0.5 ± 2.5 0.4852
Handgrip right (kg) 20.8 ± (10.3) (8–50) −2.5 ± 3.5 −2.3 ± 2.3 −1.2 ± 2.6 0.7408
Quadriceps (Nm) 136 ± 59 (31–220) −11.4 ± 90.4 −17.5 ± 55.1 −25.5 ± 49.5 0.9021
Biceps (Nm) 203 ± 133 (11–310) +12.2 ± 186.9 −36.0 ± 120.6 −63.4 ± 114.4 0.3456
Neuromuscular Symptom Score 35.4 ± 4.9 (23–41) −0.3 ± 1.6 −2.4 ± 5.0 −0.4 ± 1.5 0.1467
Timed Function Test (sec.)
Stair climbing 6.8 ± 5,4 (3–25) +0.8 ± 1.8 +0.3 ± 1.1 +0.5 ± 1.7 0.8478
Running 10 meters 16.9 ± 5.9 (8–30) +1.6 ± 2.2 +1.8 ± 1.8 +1.0 ± 1.8 0.3689
Getting up from sitting 2.0 ± 2.3 (0.5-10) +0.3 ± 1.4 +0.4 ± 1.0 +0.6 ± 1.6 0.4875
Getting up from lying 4.1 ± 4,8 (1–20) +0.5 ± 1.1 +1.3 ± 3.2 +0.5 ± 1.2 0.3909
Vignos Scale 2.4 ± 0.6 (2–4) +0.2 ± 0.6 +0.3 ± 0.6 0 ± 0.3 0.0712
Hammersmith Motor Ability Score 23.8 ± 6.1 (10–35) −2.3 ± 3.1 −2.1 ± 2.3 −1.0 ± 1.5 0.0578
Clinical Global Impressions – severity 4.5 ± 1.4 (3–6) −0.2 ± 1.0 +0.3 ± 0.6 +0.1 ± 1.0 0.3517
†: The column shows arithmetic mean ± standard deviations ±minimum and maximum values.
*: The column shows arithmetic mean ± standard deviations for changes between end and begin of each study period. Deflazacort and placebo values are pooled
across both crossover periods.
‡: p-values associated with the treatment effect in Lehmacher’s (1991) proposal for the non-parametric analysis of crossover-data (deflazacort vs. Placebo). Neither
carry-over nor period effects were detected in any analysis.
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Figure 5 (See legend on next page.)
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data). If a reduction in dysferlin-expression would occur in
dysferlinopathy patients, then it would affect patients
with residual or partially functional dysferlin protein
more than patients without any protein. However, we
did not obtain muscle biopsies of the patients in our
study during or after treatment.
In our trial, patients did not improve during the
deflazacort period of treatment. In contrast, under
deflazacort treatment, there was a trend to muscle
strength worsening, which recovered after discontinuation
of the study drug during the wash-out period. In patients
with residual dysferlin protein levels, the negative effect of
deflazacort was more pronounced than in patients with
absent dysferlin protein. However, due to the small sample
size of the subgroups, this finding is mainly hypothetic
and has not been described before, but we may speculate
that steroids have a negative effect on dysferlin expression
or function.
In contrast, Belanto et al. [33] hypothesized that a
key therapeutic benefit of glucocorticoids may be the
up-regulation of dysferlin as an important component
of glucocorticoid-enhanced myogenic differentiation.
However, this was based on experimentation in
cultured C2C12 cells that may not be an adequate model
for adult, dystrophic muscle. Further work is required to
understand the exact molecular action of steroids on
dysferlin expression or function in mammalian muscle,
whether it is a direct or an indirect effect.
The SF-36 scores in subscales physical role function
and general health perception as well in the standardized
physical component scale at baseline showed similar
values in dysferlinopathies as in other chronic diseases,
and improved slightly during the 1-year natural history
phase, possibly due to better patient support and care
during the ongoing clinical trial. No impaired quality of
life compared to the German general population were
observed in the emotional subscales of the SF-36.
During deflazacort treatment - in line with the results of
the other outcome measures, e.g. strength testing - SF-
36 ratings worsened in all subscales, but remained stable
or improved slightly during placebo administration, most
pronounced for mental health, emotional role and
vitality subscales and the standardized mental compo-
nent scale. The CGI global severity score did not change
(See figure on previous page.)
Figure 5 Neuromuscular Symptom Score (NSS) in both groups in 18 patients (sequence deflazacort-placebo, and placebo-deflazacort,
completer population). a) Average course%NSS sum score from natural history until end of both sequences. b) Mutation-related NSS subgroup
analysis. Correlation between the type of mutation, resulting in residual dysferlin protein versus total loss of dysferlin protein, assessed by Western
Blot and mutation prediction, and outcomes during treatment phases with a sample size of 4 patients in 3 subgroups (sequence deflazacort-
placebo, protein present / sequence deflazacort-placebo, protein absent / sequence placebo-deflazacort, protein present) and 6 patients in the
remaining subgroup (sequence placebo-deflazacort, protein absent).
Table 2 Health-related quality of life assessment with the sf-36: baseline data and changes during study phases
SF-36 scale Baseline† Natural history Deflazacort (pooled) Placebo (pooled) p-value
End of year
1 – begin*
End – begin
of crossover*
End – begin
of crossover*
Deflazacort
vs. placebo‡
Subscales
Physical functioning 38.3 ± 19.8 (5–85) −0.1 ± 13.4 −6.8 ± 9.3 +1.5 ± 11.1 0.118
Role Physical 70.6 ± 36.7 (0–100) +11.8 ± 46.9 −22.4 ± 32.2 +6.6 ± 38.0 0.114
Role Emotional 91.7 ± 22.8 (33–100) +6.3 ± 25.0 −14.8 ± 46.1 +13.0 ± 34.6 0.037
Social functioning 86.8 ± 12.5 (62–100) 0 ± 12.9 −5.9 ± 23.0 −3.3 ± 14.3 0.963
Mental health 79.8 ± 12.7 (44–96) −0.2 ± 5.6 −9.1 ± 9.4 +2.9 ± 14.3 0.009
Bodily pain 73.2 ± 16.2 (12–100) +7.1 ± 21.5 −1.9 ± 25.4 +3.2 ± 18.8 0.394
Vitality 60.0 ± 16.3 (40–95) +0.3 ± 11.3 −7.4 ± 16.1 +1.8 ± 11.2 0.096
General health perception 45.5 ± 14.4 (25–82) +6.0 ± 10.9 −4.3 ± 11.6 −1.7 ± 11.0 0.965
Standardized component Scales
Physical 36.4 ± 8.0 (19–50.4) +1.5 ± 5.5 −2.5 ± 6.6 +0.4 ± 5.3 0.3123
Mental 56.2 ± 5.8 (40–65) +0.6 ± 4.6 −4.2 ± 10.7 +1.6 ± 8.7 0.0922
†: The column shows arithmetic mean ± standard deviations (minimum and maximum) values. The scoring of the SF-36 scales ranges from 0 = very bad to
100 = very good quality of life in the different domains of the scale.
*: The column shows arithmetic mean ± standard deviations for changes between end and begin of each study period. Deflazacort and placebo values are pooled
across both crossover periods.
‡: p-values associated with the treatment effect in Lehmacher’s (1991) proposal for the non-parametric analysis of crossover-data (deflazacort vs. placebo).
With the exception of “role emotional”, there were no carry-over effects detected. No period effects were identified.
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comparing starting- and endpoint of the trial, suggesting
that relevant differences of disease severity were not fully
recognizable by the investigator within 27 months of the
trial duration.
During deflazacort treatment, we observed a broad
spectrum of known side effects. Our study shows that
deflazacort is not an effective therapy for dysferlinopathies,
and may even harm patients. Therefore, off-label use is not
warranted. Even if this result is not what we would have
hoped for, it is nevertheless an important finding, since
there is good reason now to definitely withhold steroid
treatment from patients with dysferlinopathy.
In this study, we were able to establish data regarding
the natural course of dysferlinopathies that improve our
understanding of the clinical problems these patients are
confronted with and may serve as reference for future
studies. As measures of muscular function in our sample
of juvenile and adult ambulatory patients, CIDD, HHD
and NSS have proven useful in showing a change in
muscle strength and daily activities within one to two
years, while timed tests seemed not suitable. Additionally
it became clear that a quality of life measure, specifically
adapted on patients with muscle diseases would be
warranted, since SF-36 and CGI do not adequately mirror
the specific problems of muscular dystrophy patients.
Although no major therapeutic breakthrough has been
achieved and curative treatment modalities are not yet
applicable, life expectancy and quality of life of
dysferlinopathy patients could be remarkably improved
by establishing a drug therapy, capable of delaying the
dystrophic process and improving muscle strength and
function. Unfortunately, no such therapy is available yet,
and treatment of dysferlinopathies is mainly based on
symptomatic treatment. Therefore, the results of this
clinical trial – even being negative - are warranted and
may influence further guidelines for steroid treatment in
dysferlinopathies. Furthermore, our assessment of the
natural history of the disease will provide new insights
in the clinical understanding of dysferlinopathies [34].
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